402718-29-0

Usage

Uses

Used in Organic Synthesis:
3-Cyanopyridine-5-boronic acid pinacol ester is used as a building block for the preparation of various biologically active compounds and pharmaceuticals. Its versatility in cross-coupling reactions and other synthetic transformations allows for the creation of a wide range of molecules with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Cyanopyridine-5-boronic acid pinacol ester is utilized for the development of new pharmaceuticals. Its ability to participate in various synthetic pathways contributes to the discovery and synthesis of novel drug candidates.
Used in Fluorescent Probe Development:
3-Cyanopyridine-5-boronic acid pinacol ester is used as a fluorescent probe for the detection of certain metal ions. This application takes advantage of its potential to emit fluorescence upon interaction with specific metal ions, facilitating the study and analysis of these ions in various chemical and biological contexts.
Used in Coordination Chemistry:
As a ligand in coordination chemistry, 3-Cyanopyridine-5-boronic acid pinacol ester is employed for the formation of coordination complexes. This use is valuable for understanding the interactions between metal ions and organic ligands, which can be crucial in the design of new materials and catalysts.
Overall, 3-Cyanopyridine-5-boronic acid pinacol ester's applications span across multiple scientific disciplines, highlighting its significance in the advancement of chemical and pharmaceutical research.

InChI:InChI=1/C12H15BN2O2/c1-11(2)12(3,4)17-13(16-11)10-5-9(6-14)7-15-8-10/h5,7-8H,1-4H3

Upstream product

• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 73183-34-3 bis(pinacol)diborane 
• 100-54-9 pyridine-3-carbonitrile 

Downstream Products

• 1227163-67-8 5-(5-(3-Amino-4-fluoro-1-(pyridin-4-yl)-1H-isoindol-1-yl)-2-fluorophenyl)nicotinonitrile 
• 1259380-34-1 5-(4-(7'-methoxy-5'H-spiro[piperidine-4,4'-pyrrolo[1,2-a]quinoxaline]-1-ylcarbonyl)phenyl)nicotinonitrile hydrochloride 
• 887579-69-3 tert-butyl 5-cyanonicotinate 
• 152803-24-2 5-hydroxypyridine-3-carbonitrile 
• 10177-11-4 5-phenylnicotinonitrile 
• 1414877-87-4 5-[3-((4R,5R)-2-{[bis-(4-methoxy-phenyl)-phenyl-methyl]-amino}-5-fluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-nicotinonitrile 
• 1297596-82-7 5'-(5-cyano-pyridin-3-yl)-3'-(4-methoxy-phenoxy)-2,3,5,6-tetrahydro-[1,2]bipyrazinyl-4-carboxylic acid tert-butyl ester 
• 1260432-22-1 5-(3-(4-amino-2-(4-methoxyphenyl)-5-methyl-2H-imidazol-2-yl)phenyl)nicotinonitrile 
• 1083428-87-8 5-[6-(4-methanesulfonyl-phenyl)-2-methyl-imidazo[1,2-b]pyridazin-3-yl]-nicotinonitrile 
• 1447908-57-7 5-((6-phenylpyridin-3-yl)methyl)nicotinamide 

Relevant academic research and scientific papers

Two Ligands Transfer from Ag to Pd: En Route to (SIPr)Pd(CF2H)(X) and Its Application in One-Pot C-H Borylation/Difluoromethylation

A process for the concurrent transfer of both the NHC ligand and the difluoromethyl group from [(SIPr)Ag(CF2H)] to PdX2 (X = Cl, OAc, and OPiv) for the preparation of [(SIPr)Pd(CF2H)X] complexes is described. These complexes were air-stable and easily underwent transmetalation with aryl pinacol boronate/reductive elimination to generate ArCF2H in high yields. Based on this discovery, the first one-pot C-H borylation and difluoromethylation process for the preparation of difluoromethylated (hetero)arenes was developed.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives

4,4″-Diamidino-m-terphenyl (1) and 36 analogues were prepared and assayed in vitro against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Plasmodium falciparum, and Leishmania amazonensis. Twenty-three compounds were highly active against T. b. rhodesiense or P. falciparum. Most noteworthy were amidines 1, 10, and 11 with IC50 of 4 nM against T. b. rhodesiense, and dimethyltetrahydropyrimidinyl analogues 4 and 9 with IC50 values of ≤ 3 nM against P. falciparum. Bis-pyridylimidamide derivative 31 was 25 times more potent than benznidazole against T. cruzi and slightly more potent than amphotericin B against L. amazonensis. Terphenyldiamidine 1 and dipyridylbenzene analogues 23 and 25 each cured 4/4 mice infected with T. b. rhodesiense STIB900 with four daily 5 mg/kg intraperitoneal doses, as well as with single doses of ≤10 mg/kg. Derivatives 5 and 28 (prodrugs of 1 and 25) each cured 3/4 mice with four daily 25 mg/kg oral doses.

PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to pyrazolopyridyl compounds of the structural formula: [Formula should be inserted here] or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone s

Pyrrolopyrimidines and Pyrrolopyridines

Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Cyclobutyl amine derivatives

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compoun